FLKS Flex Pharma, Inc.

3.07
+0  (0%)
Previous Close 3.06
Open 3.08
Price To book 0.87
Market Cap 51.49M
Shares 16,773,000
Volume 42,962
Short Ratio 5.96
Av. Daily Volume 64,371

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated in 2017.
FLX-787
Charcot-Marie-Tooth (CMT)
Phase 2 endpoints not met - October 2016. Announced January 24, 2017 that other indications will take priority over nocturnal leg cramps.
FLX-787
Nocturnal Leg Cramp
Phase 2 data due by the end of 2017.
FLX-787
Multiple Sclerosis
Phase 2 initiated September 2016. Readout due 2017/18.
FLX-787
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND
  2. Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting
  3. Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
  4. Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventing And Treating Muscle Cramps
  5. Edited Transcript of FLKS earnings conference call or presentation 8-Mar-17 1:30pm GMT
  6. Flex Pharma reports 4Q loss
  7. Flex Pharma Reports Year End 2016 Financial Results
  8. Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017
  9. Champion Triathlete Finds Solution For Struggle With Muscle Cramps
  10. Flex Pharma to Present at the BIO CEO & Investor Conference
  11. Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases
  12. Champion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps
  13. Do Hedge Funds Love Vishay Precision Group Inc (VPG)?
  14. Flex Pharma to Present at the Piper Jaffray 28th Annual Healthcare Conference
  15. Flex Pharma to Present at the Jefferies 2016 Healthcare Conference
  16. Edited Transcript of FLKS earnings conference call or presentation 2-Nov-16 12:45pm GMT
  17. Flex Pharma Reports Third Quarter 2016 Financial Results
  18. Flex Pharma to Report Third Quarter 2016 Results on November 2, 2016
  19. Flex Pharma Provides FLX-787 Nocturnal Leg Cramp Regulatory and Clinical Update

SEC Filings

  1. DEF 14A - Other definitive proxy statements 17770145
  2. 8-K - Current report 17742348
  3. S-8 - Securities to be offered to employees in employee benefit plans 17675371
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17675235
  5. 8-K - Current report 17673912
  6. 8-K - Current report 17630835
  7. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17586441
  8. 8-K - Current report 17567424
  9. 8-K - Current report 162053150
  10. 8-K - Current report 161997851